On June 25, 2009, Liu, Julie published a patent.Reference of (S)-2-Hydroxy-N-methyl-2-phenylacetamide The title of the patent was Preparation of tetrahydroisoquinoline derivatives as orexin receptor antagonists. And the patent contained the following:
This title compounds with general formula I [wherein each Z is independently selected from hydrogen or deuterium; each R is independently selected from CD3, CD2H, CDH2, or CH3, and when each R is CH3 then at least one Z is deuterium] or pharmaceutically acceptable salts thereof were prepared as dual OX-1/OX-2 orexin receptor antagonists for the treatment of obesity, bulimia, anorexia nervosa, insomnia, narcolepsy, sleep apnea, jet-lag syndrome, or memory impairment. For example, compound II·HCl was prepared in a multi-step synthesis, with the last step being the condensation of (1S)-[1,2,3,4-tetrahydro-3,3,4,4-d4]-[6,7-dimethoxy-d6]-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-isoquinoline hydrochloride (preparation given) and toluene-4-sulfonic acid [(S)-1-[(methyl-d3)carbamoyl]-1-phenylmethyl] ester (preparation given). The metabolic stability of compounds I has been tested using pooled liver microsomal incubation. The experimental process involved the reaction of (S)-2-Hydroxy-N-methyl-2-phenylacetamide(cas: 65645-88-7).Reference of (S)-2-Hydroxy-N-methyl-2-phenylacetamide
The Article related to preparation tetrahydroisoquinoline orexin receptor antagonist treatment eating disorder sleep, treatment obesity bulimia anorexia nervosa insomnia narcolepsy sleep apnea, human jet lag syndrome memory impairment treatment and other aspects.Reference of (S)-2-Hydroxy-N-methyl-2-phenylacetamide
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics